BB Biotech Shareholders Back Board and Approve CHF 2.25 Dividend

BB Biotech ( (CH:BION) ) has issued an announcement.

Shareholders of BB Biotech AG have approved all proposals put forward at the ordinary General Meeting, underscoring continuity in both the company’s governance and its strategy as a specialized biotech investment vehicle. The existing Board of Directors, including Chairman Dr. Thomas von Planta and four other members, was re-elected for another one-year term, signaling investor confidence in the current leadership.

The meeting also authorized a gross dividend of CHF 2.25 per share, with payment scheduled for March 25, 2026, reinforcing the firm’s commitment to providing regular cash returns to investors. This combination of an unchanged board and a maintained dividend policy highlights BB Biotech’s stable positioning in the biotech investment market and offers predictability for shareholders seeking both sector exposure and income.

The most recent analyst rating on (CH:BION) stock is a Buy with a CHF66.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.

More about BB Biotech

BB Biotech AG is a Swiss investment company based in Schaffhausen and listed on the Swiss and German stock exchanges. Since 1993, it has focused on investing in innovative drug development companies, primarily in the U.S. and Western Europe, and is regarded as one of the leading investors in this biotechnology sector.

The company’s investment strategy and guidelines are set by an experienced Board of Directors, while portfolio decisions are executed by Bellevue Asset Management’s dedicated Investment Management Team, which relies on in-depth research to identify and manage biotech opportunities for shareholders.

Average Trading Volume: 87,625

Technical Sentiment Signal: Buy

Current Market Cap: CHF2.48B

For a thorough assessment of BION stock, go to TipRanks’ Stock Analysis page.